178 research outputs found
Automated Decision Support and Guideline Verification in Clinical Practice
Applying international guidelines in medical, including cardiological, therapies is a guarantee of safe and modern treatment. Unfortunately, standards are often not obeyed. In this paper we present an experimental software program based on rough sets methods. The main aim of this application is to improve patient care and help the decision process using guidelines verification. We concentrate on the practical aspects using these methods. Examples and clinical tests, which were based on real-life data of our patients, show that the accuracy of results reached on a large group of patients could be acceptable in clinical practice. 1
From bare metal powders to colloidally stable TCO dispersions and transparent nanoporous conducting metal oxide thin films
A simple, green, robust, widely applicable, multi-gram and cost-effective 'one-pot' synthesis of aqueous dispersions of colloidally stable 3-6 nm TCO NPs using bare metal powder precursors is described, and their utilization for making TCO high surface area nanoporous films is also demonstrated, which speaks well for their usage in a wide range of possible processes and devices. Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
From Bare Metal Powders to Colloidally Stable TCO Dispersions and Transparent Nanoporous Conducting Metal Oxide Thin Films
Cataloged from PDF version of article.A simple, green, robust, widely applicable, multi-gram and cost-effective 'one-pot' synthesis of aqueous dispersions of colloidally stable 3-6 nm TCO NPs using bare metal powder precursors is described, and their utilization for making TCO high surface area nanoporous films is also demonstrated, which speaks well for their usage in a wide range of possible processes and devices. Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Limited Lifespan of Fragile Regions in Mammalian Evolution
An important question in genome evolution is whether there exist fragile
regions (rearrangement hotspots) where chromosomal rearrangements are happening
over and over again. Although nearly all recent studies supported the existence
of fragile regions in mammalian genomes, the most comprehensive phylogenomic
study of mammals (Ma et al. (2006) Genome Research 16, 1557-1565) raised some
doubts about their existence. We demonstrate that fragile regions are subject
to a "birth and death" process, implying that fragility has limited
evolutionary lifespan. This finding implies that fragile regions migrate to
different locations in different mammals, explaining why there exist only a few
chromosomal breakpoints shared between different lineages. The birth and death
of fragile regions phenomenon reinforces the hypothesis that rearrangements are
promoted by matching segmental duplications and suggests putative locations of
the currently active fragile regions in the human genome
Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign
Aims/hypothesis
The aim of this study was to study dynamic changes in the prevalence of different types of diabetes in paediatric populations in Poland, with a specific focus on monogenic diabetes (MD).
Methods
Using epidemiologic data (PolPeDiab Collaboration) and nationwide genetic test results (TEAM Programme), we compared the prevalence of type 1, type 2 and cystic fibrosis-related diabetes (CFRD) and MD. Genetically confirmed MD included MODY, neonatal diabetes and Wolfram and Alström syndromes. The study covered all children aged 0-18 years treated for diabetes between 2005 and 2011 in three regions, inhabited by 23.7% (1,989,988) of Polish children, with a low prevalence of childhood obesity (<5%).
Results
The prevalence of type 1 diabetes showed a continuous increase, from 96 to 138/100,000 children. The prevalence of type 2 diabetes and CFRD also increased, from 0.3 to 1.01/100,000 children and from 0.1 to 0.95/100,000 children, respectively. The prevalence of MD was stable at between 4.2 and 4.6/100,000 children, accounting for 3.1-4.2% of children with diabetes, with glucokinase (GCK)-MODY being the most frequent type, amounting to 83% of patients with MD. The percentage of positive test results decreased with the number of referrals, suggesting that children with the highest probability of MD were referred initially, followed by those with a less clear-cut phenotype. The prevalence of neonatal diabetes equalled 1 in 300,000 children.
Conclusions/interpretation
The prevalence of MD in a paediatric population with a low prevalence of obesity remains stable and is nearly fivefold higher than that of type 2 diabetes and CFRD, justifying a need for increased access to genetic diagnostic procedures in diabetic children
Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births
Item does not contain fulltex
Association Between CNDP1 Genotype and Diabetic Nephropathy Is Sex Specific
OBJECTIVE-The 5-5 homozygous CNDP1 (carnosinase) genotype is associated with a reduced risk of diabetic nephropathy. We investigated whether this association is sex specific and independent of susceptibility for type 2 diabetes. RESEARCH DESIGN AND METHODS-Three separate groups of 114, 90, and 66 patients with type 2 diabetes and diabetic nephropathy were included in this study and compared with 93 patients with type 2 diabetes for >15 years without diabetic nephropathy and 472 population control subjects. The diabetes control group was used to determine an association in the three patient groups separately, and the population control group was used to estimate the genotype risk [odds ratio (CI)] for the population in a pooled analysis. The population control subjects were also compared with 562 patients with type 2 diabetes without diabetic nephropathy to determine whether the association was independent of type 2 diabetes. The CNDP1 genotype was determined by fragment analysis after PCR amplification. RESULTS-The frequency of the 5-5 homozygous genotype was 28, 36, and 41% in the three diabetic nephropathy patient groups and 43 and 42% in the diabetic and population control subjects, respectively. The 5-5 homozygous genotype occurred significantly less frequently in women in all three patient groups compared with diabetic control subjects. The genotype risk for the population was estimated to be 0.5 (0.30-0.68) in women and 1.2 (0.77-1.69) in men. The 562 patients with type 2 diabetes without diabetic nephropathy did not differ from the general population (P = 0.23). CONCLUSIONS-This study suggests that the association between the CNDP1 gene and diabetic nephropathy is sex specific and independent of susceptibility for type 2 diabetes. Diabetes 59:1555-1559, 201
Is FLT3 internal tandem duplication an unfavorable risk factor for high risk children with acute myeloid leukemia? : Polish experience
According to the AML-BFM 2004 Interim, a treatment protocol used in Poland since 2005, presence of FLT3
internal tandem duplication (FLT3/ITD) qualifies a patient with acute myeloid leukemia (AML) to a high-risk group (HRG).
The present study was aimed to identify the prevalence of FLT3/ITD in children with AML in Poland and to evaluate its
prognostic significance in the HRG patients.
Out of 291 children with de novo AML treated in 14 Polish centers between January 2006 and December 2012, samples
from 174 patients were available for FLT3/ITD analysis. Among study patients 108 children (61.7%) were qualified to
HRG. Genomic DNA samples from bone marrow were tested for identification of FLT3/ITD mutation by PCR
amplification of exon 14 and 15 of FLT3 gene. Clinical features and treatment outcome in patients with and without
FLT3/ITD were analyzed in the study.
The FLT3/ITD was found in 14 (12.9%) of 108 HRG children. There were no significant differences between children with
and without FLT3/ITD in age and FAB distribution. The white blood cells count in peripheral blood at diagnosis was
significantly higher (p <0.01) in the children with FLT3/ITD. Over 5-year overall survival rate for FLT3/ITD positive
children was worse (42.4%) comparing to FLT3/ITD negative children (58.9%), but the statistical difference was not
significant. However, over 5-year survivals free from treatment failures were similar.
The FLT3/ITD rate (12.9%) observed in the study corresponded to the published data. There was no significant impact of
FLT3/ITD mutation on survival rates, although further studies are needed on this subject
Contrast-enhanced whole-heart coronary MRA at 3.0T for the evaluation of cardiac venous anatomy
This study was designed to evaluate the value of contrast-enhanced whole-heart coronary MRA (CMRA) at 3.0T in depicting the cardiac venous anatomy. In cardiac resynchronization therapy (CRT), left ventricular (LV) pacing is achieved by positioning the LV lead in one of the tributaries of the coronary sinus (CS). Pre-implantation knowledge of the venous anatomy may help determine whether transvenous LV lead placement for CRT is feasible. Images of 51 subjects undergoing contrast-enhanced whole-heart CMRA at 3.0T were retrospectively analyzed. Data acquisition was performed using electrocardiography-triggered, navigator-gated, inversion-recovery prepared, segmented gradient-echo sequence. A 32-element cardiac coil was used for data acquisition. The visibility of the cardiac veins was graded visually using a 4-point scale (1: poor–4: excellent). The paired Student t test was used to evaluate differences in diameters of the ostium of the CS in anteroposterior and superoinferior direction. The cardiac veins were finally evaluated in 48 subjects with three anatomic variations. The diameter of the CS ostium in the superoinferior direction (1.13 ± 0.26 cm) was larger than in the anteroposterior direction (0.82 ± 0.19 cm) (P < 0.05). The mean visibility score of CS, posterior interventricular vein, posterior vein of the left ventricle, left marginal vein, and anterior interventricular vein was 4.0 ± 0.0, 3.4 ± 0.5, 3.4 ± 0.5, 3.0 ± 0.8, and 3.3 ± 0.5, respectively. In conclusion, contrast-enhanced whole-heart CMRA at 3.0T can depict the normal and variant cardiac venous anatomy
- …